Studies Identify Risk Factors for Long COVID

Two recent papers provide insight into possible risk factors for developing the chronic condition, including autoantibodies and diabetes.

Written byNatalia Mesa, PhD
| 4 min read
blue gloved hand putting vial of blood into machine
Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

For long COVID sufferers, feelings of fatigue, breathing difficulties, and other debilitating symptoms persist for weeks or months after infection with SARS-CoV-2. According to one estimate, up to 60 percent of people who’ve had COVID-19 still have symptoms six months later, and the condition can arise even after mild cases of the respiratory disease. The reason why remains largely a mystery.

Two new studies are finally providing some answers. The first, published in Cell on Monday (January 24), followed 200 patients over two to three months following their COVID-19 diagnoses. The researchers determined four biological factors that they say are associated with whether a person will develop long COVID. These factors, the researchers suggest, could point to ways to prevent or treat long COVID—also known as post-acute sequelae of COVID-19 (PASC)—if identified early in an infection.

The first factor is the level of RNA in the blood at diagnosis, which ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • A black and white headshot

    As she was completing her graduate thesis on the neuroscience of vision, Natalia found that she loved to talk to other people about how science impacts them. This passion led Natalia to take up writing and science communication, and she has contributed to outlets including Scientific American and the Broad Institute. Natalia completed her PhD in neuroscience at the University of Washington and graduated from Cornell University with a bachelor’s degree in biological sciences. She was previously an intern at The Scientist, and currently freelances from her home in Seattle. 

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies